kabutan

Kubota Pharmaceutical Holdings Co., Ltd.(4596) Summary

4596
TSE Growth
Kubota Pharmaceutical Holdings Co., Ltd.
116
JPY
-4
(-3.33%)
Mar 13, 3:30 pm JST
0.72
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
116.3
Mar 13, 11:56 pm JST
Summary Chart Historical News Financial Result
PER
PBR
7.38
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
117 JPY 0.73 USD
Previous Close Mar 12
120 JPY 0.75 USD
High Mar 13, 9:00 am
118 JPY 0.74 USD
Low Mar 13, 9:51 am
113 JPY 0.70 USD
Volume
3,975,600
Trading Value
0.46B JPY 2.88M USD
VWAP
115.44 JPY 0.72 USD
Minimum Trading Value
11,600 JPY 72 USD
Market Cap
0.01T JPY 0.08B USD
Number of Trades
1,126
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
1,148
1-Year High Sep 3, 2025
18,100
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 30,000 6,552,500 218.42
Feb 27, 2026 14,000 4,907,700 350.55
Feb 20, 2026 200 4,504,100 22520.50
Feb 13, 2026 0 2,967,800
Feb 6, 2026 21,500 3,762,700 175.01
Company Profile
Kubota Pharmaceutical Holdings Co., Ltd. is a venture company focused on developing treatments for eye diseases. The company is currently concentrating on developing corrective glasses for myopia. Drug development projects have been suspended.
Sector
Pharmaceuticals
Kubota Pharmaceutical Holdings Co., Ltd. is committed to developing innovative treatments and medical technologies as an ophthalmic medical solutions company. The company aims to contribute to maintaining and restoring vision for patients with eye diseases by developing and commercializing innovative pharmaceuticals and medical devices. Their main focus is in the medical device field, with emphasis on the "Kubota Glass," a wearable device for myopia control using proprietary active stimulation technology. They are also developing "eyeMO," an ultra-compact OCT for home-based ophthalmic care. In the small molecule compound area, they are advancing the development of emixustat hydrochloride as a treatment for Stargardt disease, based on visual cycle modulation technology. The company is actively pursuing partnership strategies with other companies to expand their pipeline and is also exploring M&A opportunities.